Skip to main content
SpringerLink
Log in

Kollagenosen

  • Chapter
  • First Online:
Rheumatologie aus der Praxis

  • 4345 Accesses

Zusammenfassung

Zu den Kollagenosen gehören: der systemische Lupus erythematodes (SLE), die Mischkollagenose (Mixed Connective Tissue Disease – MCTD, Sharp-Syndrom), die systemische Sklerose, das Sjögren-Syndrom und die systemischen Myositiden. Der Beitrag umfasst die Beschreibung der wichtigsten Krankheiten unter Berücksichtigung neuer Klassifikationskriterien und neuer Erkenntnisse in der Behandlung. Mehrere Fallbeispiele tragen zum Verständnis diagnostischer Schritte und komplexer Therapieentscheidungen bei.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology 48 [Suppl 3]:iii 3–7 (Review)

    CAS  Google Scholar 

  2. Amato AA, Griggs RC (2003) Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 16:569–575

    Article  CAS  PubMed  Google Scholar 

  3. Andreoli L, Bertsias GK, Agmon-Levin N et al. (2016) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis Jul 25. Epub ahead of print. doi: 10.1136/annrheumdis-2016-209770

  4. Aringer M, Hiepe S (2011) Systemischer Lupus erythematodes. Z Rheumatol 70:313–323

    Article  CAS  PubMed  Google Scholar 

  5. Aringer M, Steiner G, Smolen JS (2005) Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 31:411–442

    Article  PubMed  Google Scholar 

  6. Bertsias GK, Ionnidis JPA, Boletis J et al. (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 67:195–205

    Article  CAS  PubMed  Google Scholar 

  7. Bertsias GK, Ioannidis JP, Aringer M et al. (2010) EULAR recommendations for the management of systemic lupus erythematosis with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69(12):2074–2082

    Article  CAS  PubMed  Google Scholar 

  8. Blank N, Max R, Lorenz HM (2006) The role of DMARDs in systemic sclerosis therapy. Rheumatology 45 [Suppl 3]:iii 2–4

    Google Scholar 

  9. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347

    Article  CAS  PubMed  Google Scholar 

  10. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407

    Article  CAS  PubMed  Google Scholar 

  11. Brito-Zeron P, Theander E, Baldini C et al. (2016) Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 12(2): 137–156

    Article  CAS  PubMed  Google Scholar 

  12. Cervera R, Khamashta MA, Font J et al. (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308

    Article  Google Scholar 

  13. Cipriani P, Di Benedetto P, Ruscitti P et al. (2015) Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther 17:247

    Article  PubMed  PubMed Central  Google Scholar 

  14. Cummins MJ, Papas A, Kammer GM, Fox PC (2003) Treatment of primary Sjogren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results. Arthritis Rheum 49:585–593

    Article  CAS  PubMed  Google Scholar 

  15. Distler JHW (2008) Primäres und sekundäres Raynaud Phänomen. Z Rheumatol 67:211–219

    Article  CAS  PubMed  Google Scholar 

  16. Dörner T (2008) Sjögren-Syndrom. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 817–824

    Chapter  Google Scholar 

  17. Dörner T, Gromnica-Ihle E (2006) Sjögren-Syndrom, Kapitel 4.1. In: Meyer J et al. (Hrsg) Rationelle Diagnostik und Therapie in der Inneren Medizin. Elsevier/Urban & Fischer, München

    Google Scholar 

  18. Feist E, Dörner T, Hansen A (2007) Indikation und Option neuer immunmodulatorischer Therapien beim Sjögren-Syndrom. Z Rheumatol 66:679–685

    Article  CAS  PubMed  Google Scholar 

  19. Fischer-Betz R, Schneider M (2008) Lupus erythematodes-evidenzbasierte Empfehlungen zu Überwachung und Therapie. Z Rheumatol 67:491–499

    Article  Google Scholar 

  20. Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331

    Article  CAS  PubMed  Google Scholar 

  21. Fries JF, Hochberg MC, Medsger TA et al. and ACR Diagnostic and Therapeutic Criteria Committee (1994) Criteria for rheumatic disease. Different types and different functions. Arthritis Rheum 37:454–462

    Article  CAS  PubMed  Google Scholar 

  22. Fries R, Shariat K, Wilmowsky H von, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985

    CAS  PubMed  Google Scholar 

  23. Fritzler MJ, Kinsella TD, Garbutt E (1980) The CREST syndrome: A distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526

    Article  CAS  PubMed  Google Scholar 

  24. Genth E (2008) Systemische Sklerose. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 801–816

    Chapter  Google Scholar 

  25. Ginzler EM, Dooley MA, Aranow C et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228

    Article  CAS  PubMed  Google Scholar 

  26. Gladman D, Ginzler E, Goldsmith C et al. (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369

    Article  CAS  PubMed  Google Scholar 

  27. Gromnica-Ihle E (2008) Mixed connective tissue disease (Sharp-Syndrom). In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 824–830

    Google Scholar 

  28. Hochberg MC (1997) Updating the ACR revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  PubMed  Google Scholar 

  29. Hoeper M (2003) Pulmonale arterielle Hypertonie. In: Hoeper M (Hrsg) Endothelin-Rezeptor-Antagonismus als neues Therapieprinzip bei kardiovaskulären Erkrankungen. Uni-Med, Bremen, S 30–53

    Google Scholar 

  30. Hoogen van den F, Khanna D, Fransen J et al. (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747

    Article  Google Scholar 

  31. Korn JH, Mayes M, Matucci Cerinic M et al. (2004) Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993

    Article  CAS  PubMed  Google Scholar 

  32. LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): Classification subsets and pathogenesis. J Rheumatol 15:202–205

    CAS  PubMed  Google Scholar 

  33. Masi AT, Rodnan GP, Medsger T et al. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590

    Article  Google Scholar 

  34. Matucci-Cerinic M, Krieg T, Guillevin L et al. (2016) Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis 75(19):1770–1776

    Article  CAS  PubMed  Google Scholar 

  35. Meijer J, Meiners P, Vissink A et al. (2010) Effective rituximab treatment in primary Sjögren’s syndrome: A randomised, double-blind, placebo controlled trial. Arthritis Rheum 62:960–980

    Article  CAS  PubMed  Google Scholar 

  36. Meyer O (2006) Prognostic markers for systemic sclerosis. Joint Bone Spine 73:490–494

    Article  CAS  PubMed  Google Scholar 

  37. Miyakis S, Lockshin MD, Atsumi T et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306

    Article  CAS  PubMed  Google Scholar 

  38. Navarra SV, Guzman RM, Gallacher AE et al. (2011) Efficacy and safety of belimumab in patients with systemic lupus erythematosus: a randomised, placebo controlled, phase 3 trial. Lancet 377:721–731

    Article  CAS  PubMed  Google Scholar 

  39. Pavlov-Dolijanovic S, Damanov NS, Vujasinovic Stupar NZ et al. (2013) The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud’s phenomenon. Rheumatol Int 33(12):2967–2973

    Article  CAS  PubMed  Google Scholar 

  40. Petri M, Orbai AM, Alarcon GS et al. (2012) Derivation and validation of the Sytemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686

    Article  PubMed  PubMed Central  Google Scholar 

  41. Richter J (2015) Idiopathische Myositiden - Dermatomyositis und Polymyositis. In: Hettenkofer HJ, Schneider M, Braun J (Hrsg) Rheumatologie, 6. Aufl. Thieme, Stuttgart, S 251–262

    Google Scholar 

  42. Richter J, Iking-Konert C (2007) Aktuelle Therapien der Dermatomyositis und Polymyositis. Z Rheumatol 66:686–682

    Article  CAS  PubMed  Google Scholar 

  43. Riemekasten G, Dragun D (2007) Risikoadaptierte Therapien bei der systemischen Sklerose. Z Rheumatol 66:672–678

    Article  CAS  PubMed  Google Scholar 

  44. Riemekasten G, Schulze-Koops H (2005) Medikamentöse vasoaktive Therapien von Mikrozirkulationsstörungen bei rheumatischen Erkrankungen. Z Rheumatol 64:123–136

    Article  CAS  PubMed  Google Scholar 

  45. Rösler KM, Scheidegger O (2015) Myositiden. Z Rheumatol 74:496–506

    Article  PubMed  Google Scholar 

  46. Ryden-Aulin M, Boumpas D, Bultink I et al. (2016) Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med 6;3(1): e000163

    Article  Google Scholar 

  47. Saar P, Müller-Ladner U (2006) Die systemische Sklerose – Eine rheumatologische Herausforderung. Z Rheumatol 65:429–440

    Article  CAS  PubMed  Google Scholar 

  48. Sharp GC (1987) Diagnostic criteria for classification of MCTD. In: Kaskawa R, Sharp GC (Hrsg) Mixed connective tissue disease and anti-nuclear antibodies. Elsevier, Amsterdam, S 23–32

    Google Scholar 

  49. Sharp GC, Irvin WS, Tan EM et al. (1972) Mixed connective tissue disease. An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159

    Article  CAS  PubMed  Google Scholar 

  50. Shiboski SC, Shiboski CH, Criswell L et al. (2012) New Classification Criteria for Sjögren’s Syndrome: A data-driven expert – clinician consensus approach within the SICCA Cohort. Arthritis Care Res 64:475–487

    Article  CAS  Google Scholar 

  51. Sjögren HSC (1933) Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol [Suppl II]: 1–151

    Google Scholar 

  52. Specker C (2016) Antiphospholipidsyndrom Z Rheumatol 75:570–574

    Google Scholar 

  53. Tan EM, Cohen AS, Fries JF et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  CAS  PubMed  Google Scholar 

  54. Tashkin DP, Elashoff R, Clements PJ et al., Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666

    Article  CAS  PubMed  Google Scholar 

  55. Vitali C, Bombardieri S, Jonsson R et al. (2002) European Study Group on Classification Criteria for Sjogren’s Syndrome. Classification criteria for Sjogren’s syndrome: A revised version of the European criteria proposed by the America-European Consensus Group. Ann Rheum Dis 61:554–558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Witte T (2014) Sjögren-Syndrom. Z Rheumatol 73:49–61

    Article  CAS  PubMed  Google Scholar 

  57. Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 165:2337–2344

    Article  PubMed  Google Scholar 

  58. Zuber M, Koch B, Gause A, Pfreundschuh M (1996) Diagnose und Klassifikationskriterien in der Rheumatologie: Kollagenosen. Dtsch Med Wschr 121:913–918

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internist und Rheumatologe, Freiung 19, 4600, Wels, Österreich

    Rudolf Puchner

  2. Landesklinikum Weinviertel Stockerau 2. Med. Abt. mit Schwerpunkt Rheumatologie und Endokrinologie, Niederösterreichisches Kompetenzzentrum für Rheumatologie Karl Landsteiner Institut für klinische Rheumatologie, Landstraße 18, 2000, Stockerau, Österreich

    Judith Sautner

Authors
  1. Rudolf Puchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judith Sautner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rudolf Puchner .

Editor information

Editors and Affiliations

  1. Wels, Austria

    Rudolf Puchner

Rights and permissions

Reprints and permissions

Copyright information

© 2017 © Springer-Verlag GmbH Deutschland

About this chapter

Cite this chapter

Puchner, R., Sautner, J. (2017). Kollagenosen. In: Puchner, R. (eds) Rheumatologie aus der Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-53569-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-53569-1_4

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-53568-4

  • Online ISBN: 978-3-662-53569-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation